Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes
News Nov 10, 2009
Compugen Ltd. has announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.
This new biomarker was discovered using Compugen’s GeneVa® platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides.
Predisposition markers are of particular value in diseases like type 2 diabetes, where specific lifestyle and health factors are known to play an important role. Following diagnosis, high-risk patients may benefit from more aggressive management either through lifestyle modification or drug treatment. There are an estimated 24 million people in the U.S. with diabetes, 90% of whom are affected by type 2 diabetes.
During the past few years, extensive efforts by others searching for genetic markers for type 2 diabetes have utilized numerous genome-wide association studies, involving thousands of patients globally. Several validated genetic markers have been found; however, combining all the discovered biomarkers still explains only a small fraction of the heritability of the disease, so the need for additional markers continues to exist.
From the approximately 350,000 multiple nucleotide genetic variations predicted by the GeneVa® platform, a very small set of variations was selected as being potentially related to type 2 diabetes in Caucasians. This very small set, consisting of only 135 variations, was then tested in a genotyping experiment.
In this study, CGEN-40001, a novel 15bp insertion in PFKP (a key regulatory enzyme in glycolysis), demonstrated the predicted correlation with type 2 diabetes in Caucasians. This correlation was then validated in a second study based on an independent set of samples.
According to the two studies performed by Compugen, approximately 15% of the Caucasian population has at least one copy of this insertion. Furthermore, the studies showed that the presence of this insertion increases the risk of type 2 diabetes by 50-80%.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
The Ancient Behaviour of Sleep, Conserved Throughout EvolutionNews
The finding that jellyfish sleep implies that sleep is an ancient behavior, largely untouched by millennia of evolution.READ MORE
Gene Immunotherapy Approach Prevents and Reverses Symptoms of Multiple SclerosisNews
Researchers used a viral vector to deliver a gene encoding a myelin sheath protein to the liver, thereby inducing robust and durable immune tolerance in mice by preventing T cells from attacking the myelin sheath.READ MORE